Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up.

Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT.

In Vivo. 2007 Sep-Oct;21(5):707-13.

2.

A six-month trial of valacyclovir in the Epstein-Barr virus subset of chronic fatigue syndrome: improvement in left ventricular function.

Lerner AM, Beqaj SH, Deeter RG, Dworkin HJ, Zervos M, Chang CH, Fitzgerald JT, Goldstein J, O'Neill W.

Drugs Today (Barc). 2002 Aug;38(8):549-61. Review.

PMID:
12582420
3.
4.

Prevalence of abnormal cardiac wall motion in the cardiomyopathy associated with incomplete multiplication of Epstein-barr Virus and/or cytomegalovirus in patients with chronic fatigue syndrome.

Lerner AM, Dworkin HJ, Sayyed T, Chang CH, Fitzgerald JT, Beqaj S, Deeter RG, Goldstein J, Gottipolu P, O'Neill W.

In Vivo. 2004 Jul-Aug;18(4):417-24.

5.

Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers.

Watt T, Oberfoell S, Balise R, Lunn MR, Kar AK, Merrihew L, Bhangoo MS, Montoya JG.

J Med Virol. 2012 Dec;84(12):1967-74. doi: 10.1002/jmv.23411.

6.

A virologic pilot study of valacyclovir in infectious mononucleosis.

Balfour HH Jr, Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Holman CJ, Vezina HE, Brundage RC.

J Clin Virol. 2007 May;39(1):16-21. Epub 2007 Mar 21.

PMID:
17369082
7.

Antibody to Epstein-Barr virus deoxyuridine triphosphate nucleotidohydrolase and deoxyribonucleotide polymerase in a chronic fatigue syndrome subset.

Lerner AM, Ariza ME, Williams M, Jason L, Beqaj S, Fitzgerald JT, Lemeshow S, Glaser R.

PLoS One. 2012;7(11):e47891. doi: 10.1371/journal.pone.0047891. Epub 2012 Nov 14.

8.

The role of valacyclovir on Epstein-Barr virus viral loads in pediatric liver transplantation patients.

Ozçay F, Arslan H, Bilezikçi B, Sevmiş S, Moray G, Haberal M.

Transplant Proc. 2009 Sep;41(7):2878-80. doi: 10.1016/j.transproceed.2009.07.059.

PMID:
19765462
9.

Valacyclovir treatment of chronic fatigue in adolescents.

Henderson TA.

Adv Mind Body Med. 2014 Winter;28(1):4-14.

PMID:
24445302
10.

Valacyclovir pharmacokinetics and exploratory pharmacodynamics in young adults with Epstein-Barr virus infectious mononucleosis.

Vezina HE, Balfour HH Jr, Weller DR, Anderson BJ, Brundage RC.

J Clin Pharmacol. 2010 Jul;50(7):734-42. doi: 10.1177/0091270009351884. Epub 2009 Nov 6.

12.

Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir.

Walling DM, Flaitz CM, Nichols CM.

J Infect Dis. 2003 Sep 15;188(6):883-90. Epub 2003 Sep 3.

PMID:
12964120
13.

Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi.

Olson D, Gulley ML, Tang W, Wokocha C, Mechanic O, Hosseinipour M, Gold SH, Nguluwe N, Mwansambo C, Shores C.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):112-8. doi: 10.1016/j.clml.2012.11.003. Epub 2012 Dec 20.

14.

Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.

Malouf MA, Chhajed PN, Hopkins P, Plit M, Turner J, Glanville AR.

J Heart Lung Transplant. 2002 May;21(5):547-54.

PMID:
11983544
16.
17.

Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.

Montoya JG, Kogelnik AM, Bhangoo M, Lunn MR, Flamand L, Merrihew LE, Watt T, Kubo JT, Paik J, Desai M.

J Med Virol. 2013 Dec;85(12):2101-9. doi: 10.1002/jmv.23713. Epub 2013 Aug 19.

18.

Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers.

Hoshino Y, Katano H, Zou P, Hohman P, Marques A, Tyring SK, Follmann D, Cohen JI.

J Virol. 2009 Nov;83(22):11857-61. doi: 10.1128/JVI.01005-09. Epub 2009 Sep 9.

19.

Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections.

Linde A, Andersson J, Lundgren G, Wahren B.

J Med Virol. 1987 Feb;21(2):109-21.

PMID:
3029317
20.

Epstein-Barr virus (EBV) and the chronic fatigue syndrome: normal virus load in blood and normal immunologic reactivity in the EBV regression assay.

Swanink CM, van der Meer JW, Vercoulen JH, Bleijenberg G, Fennis JF, Galama JM.

Clin Infect Dis. 1995 May;20(5):1390-2.

PMID:
7620030

Supplemental Content

Support Center